JP Morgan Chase
VIR icon

JP Morgan Chase’s Vir Biotechnology VIR Stock Holding History

JP Morgan Chase’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.33M Sell
802,597
-314,919
-28% -$3M ﹤0.01% 2974
2026
Q1 		$9.45M Buy
1,117,516
+698,913
+167% +$5.57M ﹤0.01% 2735
2025
Q4 		$2.52M Sell
418,603
-30,915
-7% -$184K ﹤0.01% 3908
2025
Q3 		$2.57M Buy
449,518
+6,143
+1% +$31.4K ﹤0.01% 3887
2025
Q2 		$2.23M Buy
443,375
+4,069
+0.9% +$21.8K ﹤0.01% 3829
2025
Q1 		$2.85M Sell
439,306
-1,367,711
-76% -$12.2M ﹤0.01% 3600
2024
Q4 		$13.3M Buy
1,807,017
+720,690
+66% +$5.68M ﹤0.01% 2432
2024
Q3 		$8.14M Sell
1,086,327
-168,971
-13% -$1.47M ﹤0.01% 2782
2024
Q2 		$11.2M Buy
1,255,298
+792,051
+171% +$7.6M ﹤0.01% 2362
2024
Q1 		$4.69M Buy
463,247
+236,700
+104% +$2.41M ﹤0.01% 3160
2023
Q4 		$2.28M Buy
226,547
+71,557
+46% +$654K ﹤0.01% 3740
2023
Q3 		$1.45M Sell
154,990
-78,529
-34% -$1.12M ﹤0.01% 3800
2023
Q2 		$5.73M Buy
233,519
+107,164
+85% +$2.69M ﹤0.01% 2759
2023
Q1 		$2.94M Sell
126,355
-23,264
-16% -$595K ﹤0.01% 3254
2022
Q4 		$3.79M Buy
149,619
+65,984
+79% +$1.62M ﹤0.01% 3056
2022
Q3 		$1.61M Buy
83,635
+679
+0.8% +$17.3K ﹤0.01% 3644
2022
Q2 		$2.11M Buy
82,956
+2,983
+4% +$69.6K ﹤0.01% 3493
2022
Q1 		$2.06M Sell
79,973
-101,849
-56% -$3.02M ﹤0.01% 3726
2021
Q4 		$7.61M Sell
181,822
-754
-0.4% -$29.5K ﹤0.01% 2690
2021
Q3 		$7.95M Sell
182,576
-27,652
-13% -$1.2M ﹤0.01% 2607
2021
Q2 		$9.94M Buy
210,228
+89
+0% +$4.05K ﹤0.01% 2441
2021
Q1 		$10.8M Buy
210,139
+64,841
+45% +$3.49M ﹤0.01% 2298
2020
Q4 		$3.89M Buy
145,298
+27,775
+24% +$903K ﹤0.01% 3006
2020
Q3 		$4.43M Sell
117,523
-4,008
-3% -$173K ﹤0.01% 2674
2020
Q2 		$4.98M Sell
121,531
-124
-0.1% -$4.16K ﹤0.01% 2463
2020
Q1 		$4.17M Buy
121,655
+21,914
+22% +$589K ﹤0.01% 2418
2019
Q4 		$1.25M Buy
+99,741
New +$1.34M ﹤0.01% 3691

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

JP Morgan Chase's VIR Position: Q2 2026 in Review

JP Morgan Chase reduced its Vir Biotechnology (VIR) stake by 28% in Q2 2026, selling an estimated $3M and leaving 802,597 shares worth $8.33M. The position accounts for ﹤0.01% of the portfolio, ranked #2974.

JP Morgan Chase first reported a position in VIR in Q4 2019 and has held it in 27 quarters since. The position peaked at $13.3M in Q4 2024. 238 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

  • JP Morgan Chase held 802,597 shares of Vir Biotechnology worth $8.33M as of Q2 2026.
  • JP Morgan Chase sold 314,919 Vir Biotechnology shares in Q2 2026, an estimated $3M.
  • Vir Biotechnology made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #2974 holding.
  • JP Morgan Chase first reported a position in Vir Biotechnology in Q4 2019 and has held it in 27 quarters since.
  • JP Morgan Chase's Vir Biotechnology position peaked at $13.3M in Q4 2024.
  • 238 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.